MRD Monitoring in Lung Cancer After Resection
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04976296|
Recruitment Status : Not yet recruiting
First Posted : July 26, 2021
Last Update Posted : August 4, 2021
|Condition or disease||Intervention/treatment|
|Lung Cancer||Diagnostic Test: MRD detection|
|Study Type :||Observational|
|Estimated Enrollment :||300 participants|
|Official Title:||Dynamic Molecular Residual Disease Detection in Stage I-IIIA Non-Small Cell Lung Cancer After Radical Resection|
|Estimated Study Start Date :||September 1, 2021|
|Estimated Primary Completion Date :||December 30, 2027|
|Estimated Study Completion Date :||December 30, 2027|
Stage I-IIIA NSCLC patients after complete resection
For stage I-IIIA NSCLC patients who underwent complete resection.
Diagnostic Test: MRD detection
The Geneplus OncoMRD lung assay is used to detect the MRD status.
Other Name: Geneplus OncoMRD lung assay
- The prognostic value of MRD [ Time Frame: 5 year ]The survival difference between MRD positive and MRD negative patients.
- The predictive value of MRD [ Time Frame: 5 year ]The separative value adjuvant chemotherapy or target therapy in MRD positive population and MRD negative population.
- The lead time of MRD [ Time Frame: 5 year ]The median lead time of detectable MRD before regular imaging finding.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04976296
|Contact: Xue-Ning Yang, Ph.Demail@example.com|
|Contact: Jia-Tao Zhang, Ph.D||020-83827812-51311||Z18820792959@hotmail.com|
|Guangdong Lung Cancer Institute & Guangdong Provincial People's Hospital|
|Guangzhou, Guangdong, China, 510030|
|Contact: Xue-Ning Yang, Ph.D 020-83827812-51311 firstname.lastname@example.org|
|Contact: Jia-Tao Zhang, Ph.D 020-83827812-51311 Z18820792959@hotmail.com|